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Accumulating evidence indicates that cyclin depen-
dent kinase 5 (Cdk5), through phosphorylating a pleth-
ora of pre- and postsynaptic proteins, functions as an
essential modulator of synaptic transmission. Recent
advances in the field of Cdk5 research have not only
consolidated the in vivo importance of Cdk5 in neuro-
transmission but also suggest a pivotal role of Cdk5 in
the regulation of higher cognitive functions and neu-
rodegenerative diseases. In this review, we will dis-
cuss the recent findings on the emanating role of Cdk5
as a regulator of synaptic functions and plasticity.
Cdk5, a proline-directed serine/threonine kinase, is
a unique Cdk that is activated by two noncyclin activa-
tors, p35 and p39. As a predominantly neural-specific ki-
nase, Cdk5 lacks a role in cell-cycle control but is impli-
cated in an astounding array of neuronal functions,
including neuronal survival, axon guidance and neuronal
migration. The ever expanding list of Cdk5 substrates as
well as the functions modulated by Cdk5 have recently
been reviewed elsewhere (Cheung and Ip, 2004; Cruz
and Tsai, 2004; Dhavan and Tsai, 2001) and, hence,
will not be the focus of the current review. Among the
various biological functions implicated, the emerging
role of Cdk5 as a regulator of neurotransmission and
synaptic plasticity has attracted increasing attention
(Cheng and Ip, 2003). Indeed, a myriad of pre- and post-
synaptic proteins have been identified as Cdk5 sub-
strates. More importantly, accumulating evidence has
lent support for an in vivo role of Cdk5 in the regulation
of neurotransmission and synaptic functions in learning
and neurodegenerative diseases. In this review, we
summarize the latest evidence on the pre- and postsyn-
aptic roles of Cdk5 and the involvement of this kinase in
higher cognitive functions and neurodegenerative dis-
eases such as Alzheimer’s disease.
Presynaptic Roles of Cdk5
Neurotransmitter release is tightly regulated through the
precise control of the synaptic vesicle cycle, which is
comprised of Ca2+-triggered exocytosis of synaptic ves-
icles, followed by retrieval and recycling of synaptic
vesicles via clathrin-mediated endocytosis, and finally
clathrin uncoating of synaptic vesicles. Through the
phosphorylation of synapsin I, Munc18, and P/Q sub-
type voltage-dependent calcium channel (VDCC),
Cdk5 has been associated with regulating the exocyto-
*Correspondence: boip@ust.hksis episode of the synaptic vesicle cycles (reviewed in
Cheng and Ip [2003]). Interestingly, a Cdk-related kinase
Pctaire1, whose activation in vivo is attributable at least
in part to Cdk5-mediated phosphorylation (Cheng and
Ip, 2003), may also play a role in regulating exocytosis.
Pctaire1 can phosphorylate NSF, a crucial factor for syn-
aptic vesicle fusion, and thereby suppress NSF oligo-
merization, a step essential for exocytosis (Liu et al.,
2006). This observation indicates that Cdk5-mediated
activation of Pctaire1 may hinder exocytosis by sup-
pressing oligomerization of NSF, thus revealing a novel
mechanism by which Cdk5 may regulate exocytosis.
In addition to the regulation of exocytosis, Cdk5 was
also identified as a kinase for dynamin I and amphiphysin
I, proteins essential for clathrin-mediated endocytosis
(Tan et al., 2003; Tomizawa et al., 2003). Recent studies
have extended the importance of Cdk5 in synaptic vesi-
cle endocytosis through demonstrating a novel role of
Cdk5 in the modulation of phosphoinositides (PIs) sig-
naling pathways. PI(4,5)P2 has been implicated in the
plasma membrane recruitment of proteins involved in
synaptic vesicle endocytosis, thus underscoring the im-
portance of regulating PI(4,5)P2 levels and localization in
the execution of synaptic vesicle endocytosis. Interest-
ingly, PIPKIg, the kinase involved in the generation of
PI(4,5)P2, and synaptojanin 1, a PI(4,5)P2 phosphatase,
were both recently identified as substrates of Cdk5
(Lee et al., 2004, 2005). Phosphorylation of PIPKIg by
Cdk5 disrupts its association with focal adhesion protein
talin (Lee et al., 2005), an interaction that is essential for
clathrin-mediated synaptic vesicle endocytosis (Morgan
et al., 2004). Additionally, Cdk5-mediated phosphoryla-
tion of synaptojanin 1 inhibits its phosphatase activity
and recruitment to the membrane. In accordance with
the implication of synaptojanin 1 in clathrin uncoating
of synaptic vesicles, inhibition of synaptojanin 1 activity
by Cdk5 suppresses this process (Lee et al., 2004). Col-
lectively, these findings indicate that Cdk5 may poten-
tially function as a negative regulator of neurotransmitter
release. In support of this notion, Cdk5 has been impli-
cated in the inhibition of dopamine release in the striatum
(Chergui et al., 2004). Furthermore, the frequency of min-
iature endplate potential (MEPP) is increased in Cdk52/2
mice (Fu et al., 2005), thus supporting an inhibitory role of
Cdk5 in neurotransmitter release in vivo.
Postsynaptic Roles of Cdk5
Regulation of Neurotransmitter Receptor Expression
An unexpected functional role of Cdk5 at the synapse
was initially revealed through the identification of Cdk5
as a crucial mediator of neuregulin (NRG) signaling and
AChR3 expression in myotubes (Fu et al., 2001). Cdk5-
mediated phosphorylation of NRG receptor ErbB3 is re-
quired for NRG-induced ErbB3 activation, initiation of
downstream signaling, and enhancement in AChR3 tran-
scription in myotubes. A recent study revealed that
NRG-mediated transcription of neurotransmitter recep-
tor is similarly observed in cultured cerebellar granule
neurons. NRG-induced activation of ErbB4 results in
Cdk5-dependent upregulation of GABAA receptors
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14Figure 1. Postsynaptic Role of Cdk5 on the
Regulation of Synaptic Transmission
Cdk5 affects neurotransmitter receptors
expression and clustering at both the CNS
synapse (A) and the NMJ (B). (A) At the CNS
synapse, NRG-mediated transcription of
neurotransmitter receptor such as GABAA re-
ceptors requires Cdk5 activity. Nonetheless,
whether this is attributable to the demon-
strated phosphorylation of ErbB receptors
by Cdk5 in the CNS requires further investiga-
tion. On the other hand, Cdk5 may also regu-
late gene transcription by phosphorylating
transcription factor STAT3 or by regulating
histone acetylation through phosphorylation
of HDAC corepressor complex component
mSds3. Furthermore, while Cdk5 suppresses
multimerization of PSD-95 and clustering of NMDA receptors via the phosphorylation of scaffold protein PSD-95, Cdk5-mediated phosphory-
lation of NMDA receptors enhances NMDA-evoked current and LTP induction. Finally, Cdk5 also dampens dopamine signaling through phos-
phorylation of DARPP-32 at Thr 75, turning DARPP-32 into an inhibitor of PKA to reduce phosphorylation of DARPP-32 at Thr 34 and initiation of
downstream signaling. (B) At the NMJ, NRG stimulation induces Cdk5 activity, which in turn affects AChR transcription by regulating ErbB sig-
naling in the myotubes, although the precise mechanisms by which AChR transcription is regulated in vivo remain elusive. On the other hand,
Cdk5 may regulate gene transcription via phosphorylation of STAT3 or phosphorylation of HDAC corepressor complex component mSds3. Fi-
nally, although agrin-induced MuSK activation provides essential signals for maintenance of AChR clusters, recent evidence suggests that Cdk5
also modulates AChR clustering by facilitating AChR dispersal, with ACh stimulation being one of the upstream AChR dispersing signals.transcription in these CNS neurons (Xie et al., 2004) (Fig-
ure 1). Because Cdk5 has been observed to phosphory-
late ErbB2/3 in the brain (Cheung and Ip, 2004), it would
be of interest to examine if Cdk5 mediates NRG-induced
increase in GABAA receptor transcription through the
phosphorylation of ErbB4 in cerebellar granule neurons.
The mechanisms by which Cdk5 mediates NRG-in-
duced transcription of neurotransmitter receptor are
barely beginning to be unraveled. However, recent ob-
servations have provided some clues. Cdk5 may medi-
ate NRG-induced gene transcription in myotubes
through the regulation of transcription factor STAT3.
NRG treatment results in an increase in Cdk5-mediated
serine phosphorylation of STAT3, which enhances
STAT3 DNA binding activity and subsequent transcrip-
tion of c-fos. Importantly, serine phosphorylation of
STAT3 is essentially abolished in Cdk52/2 brain and
muscle, indicating that Cdk5 is a critical regulator of
this event in vivo (Fu et al., 2004). Nonetheless, with
the recent observation on the lack of abnormality at
the neuromuscular junction (NMJ) of ErbB knockout an-
imals (reviewed in Kummer et al. [2006]), the in vivo role
of NRG/ErbB in synaptic transcription and the involve-
ment of Cdk5 in neurotransmitter receptor transcription
deserves further investigation. In addition to STAT3,
Cdk5 may also affect gene transcription through the
phosphorylation of another transcription factor MEF2.
Phosphorylation of MEF2 by Cdk5 inhibits the transcrip-
tional activity of MEF2 (reviewed in Cheung and Ip
[2004]). Although modulation of MEF2 activity by Cdk5
has been associated with the regulation of neuronal
death by Cdk5 and, recently, in the death of dopaminer-
gic neuron in a model of Parkinson’s disease (Smith
et al., 2006), activity-dependent regulation of MEF2 ac-
tivity also appears to affect the number of excitatory
synapses (Flavell et al., 2006). This finding reveals an im-
portant role of MEF2 in the regulation of synapse remod-
eling, and it will be interesting to examine if MEF2 also
takes part in the regulation of neurotransmitter receptor
transcription at the synapse.Regulation of Neurotransmitter Receptor Clustering
Efficient synaptic transmission relies on precise cluster-
ing of neurotransmitter receptors. The importance of
Cdk5 in this process was recently demonstrated. PSD-
95, the major scaffold protein in the postsynaptic densi-
ties (PSDs) of CNS synapses, was identified as a novel
Cdk5 substrate. Cdk5-mediated phosphorylation of
PSD-95 suppresses PSD-95 multimerization, thereby
reducing PSD-95-dependent clustering of NMDA recep-
tor subunit NR1 and voltage-gated K+ channel Kv1.4. In-
deed, Cdk52/2 cortical neurons exhibit marked enlarge-
ment of synaptic PSD-95 clusters, suggesting that Cdk5
is essential for clustering of PSD-95 in vivo (Morabito
et al., 2004). The association of PSD-95 with a myriad
of receptors and proteins at the PSD renders the regula-
tion of PSD-95 multimerization by Cdk5 an important
mechanism for affecting PSD composition. Further char-
acterization of the downstream effects of PSD-95 phos-
phorylation may unravel more unanticipated involve-
ments of Cdk5 in the modulation of PSD organization,
as well as regulation of signaling cascades at the PSD.
Cdk5 also plays a potential role in AChR clustering and
NMJ development. In vivo examination of the NMJ phe-
notype of Cdk5 knockout mice demonstrated that the
bandwidth of AChR endplate is enlarged in Cdk52/2 di-
aphragm (Fu et al., 2005). Furthermore, AChR clusters
are significantly larger in cultured myotubes lacking
Cdk5 after agrin treatment, suggesting that Cdk5 may
negatively regulate AChR cluster size (Fu et al., 2005;
Lin et al., 2005). Additionally, Cdk5 was demonstrated
to be required for ACh-induced dispersion of AChR clus-
ters (Lin et al., 2005). ACh stimulation was observed to
enhance Cdk5 activity in the myotubes, which in turn
mediates the AChR cluster dispersing effect of ACh.
These observations collectively reveal an unexpected
role of Cdk5 in the regulation of AChR clustering at the
NMJ (Figure 1).
Regulation of Dendritic Spine Remodeling
In addition to modulating the efficiency of synaptic
transmission, regulation of dendritic spine morphology
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tic plasticity is modulated. Because spine morphogene-
sis requires coordinated regulation of the cytoskeleton
and adhesion protein, crucial modulators of actin dy-
namics such as Rho GTPases are indispensable in the
regulation of spine morphology. Identification of the
Rho GTPase Rac1 effector PAK1 as a substrate of
Cdk5 (reviewed in Cheng and Ip [2003]) suggests that
Cdk5 might regulate Rho GTPase activity. Recent iden-
tification of additional Rho GTPase regulatory factors as
Cdk5 substrates lends further support to this hypothe-
sis. GEFs (guanine nucleotide exchange factors) and
GAPs (GTPase-activating protein) are regulatory factors
exhibiting essential control on the duration of Rho
GTPase activation. Although GEFs activate Rho GTPase
by facilitating the exchange of GDP to GTP, GAPs facil-
itates inactivation of the enzyme by stimulating the GTP
hydrolysis activity of Rho GTPase. Interestingly, the Rho
GTPase Rac1 modulators GEF RasGRF2 and GAP a-
chimaerin were both recently demonstrated as Cdk5
substrates (Kesavapany et al., 2004; Qi et al., 2004). Al-
though phosphorylation of RasGRF2 by Cdk5 sup-
presses Rac activation (Kesavapany et al., 2004),
Cdk5-mediated phosphorylation of a-chimaerin ap-
pears to have no effect on its Rac1-stimulating activity
(Qi et al., 2004). Although the functional significance of
a-chimaerin phosphorylation by Cdk5 remains to be de-
termined, observations from these two studies suggest
that Cdk5 may predominantly inhibit Rac1 activity
through its phosphorylation of RasGRF2. It is also note-
worthy that density of dendritic spines is enhanced in
transgenic mice overexpressing p25, a truncated form
of Cdk5 activator p35 predominating in pathological
conditions (Fischer et al., 2005). Whether this is attribut-
able to Cdk5-mediated regulation of Rho GTPase activ-
ity and whether Cdk5/p35 similarly exhibits stimulating
effect on dendritic spines requires further characteriza-
tion. Answers to these questions will be pivotal in delin-
eating the precise involvement of Cdk5 in dendritic
spine regulation.
Regulation of Neurotransmission
Through the modulation of DARPP-32 phosphorylation,
Cdk5 has been established as an essential regulator of
dopamine signaling. Phosphorylation of DARPP-32 at
Thr34 by PKA is pivotal in the propagation of signaling
downstream of dopamine D1 receptor (D1R) activation
in the striatum. Phosphorylation of DARPP-32 at Thr75
by Cdk5, on the other hand, turns DARPP-32 into an in-
hibitor of PKA, thus dampening dopamine signaling
(Bibb, 2003). Interestingly, recent advances in the field
reveal that Cdk5 also affects dopamine signaling presyn-
aptically. Tyrosine hydroxylase (TH), the rate-limiting en-
zyme in the synthesis of catecholamines including dopa-
mine, was recently identified as a substrate of Cdk5
(Kansy et al., 2004; Moy and Tsai, 2004). Phosphorylation
of TH by Cdk5 not only enhances total TH activity but also
markedly elevates stability of the protein (Moy and Tsai,
2004). These observations implicate an important role of
Cdk5 in modulating the production of dopamine. More
importantly, inhibition of Cdk5 activity increases dopa-
mine release in striatal slices (Chergui et al., 2004). The
increased dopamine release results in elevated D1R acti-
vation, and the downstream elevation of NMDA receptoractivity. These observations collectively indicate that
regulation of Cdk5 activity will likely have far-reaching
consequences in dopamine signaling and the down-
stream interplay between dopamine and glutamate sig-
naling in the striatum.
Cdk5 in Higher Cognitive Function
and Neurodegenerative Diseases
An important development in the past few years is the in-
creasing implication of Cdk5 involvement in a myriad of
higher cognitive functions, neurodegenerative diseases,
and drug-addiction-associated neuroadaptive changes.
A number of studies have provided some much-needed
insights on the in vivo role of Cdk5 in these complex
functions.
Learning and Memory
Cdk5 was initially suggested to play a role in the regula-
tion of synaptic plasticity through its phosphorylation of
NMDA receptor subunit NR2A, where inhibition of Cdk5
activity suppresses NMDA-evoked currents and mark-
edly attenuates LTP induction in CA1 hippocampal neu-
rons. Furthermore, Cdk5 activity is enhanced during as-
sociative learning and fear conditioning (Fischer et al.,
2003). Recent in vivo studies have provided further sup-
port for a pivotal role of Cdk5 in synaptic plasticity asso-
ciated with learning and memory. For example, induc-
tion of LTD and spatial learning were both impaired in
mice lacking p35 (Ohshima et al., 2005). In addition,
the threshold for LTP induction was reduced in p352/2
mice (Wei et al., 2005). Furthermore, transient overex-
pression of p25 in transgenic mice enhances LTP and
associative learning (Fischer et al., 2005). These obser-
vations collectively suggest that Cdk5 activity is crucial
for synaptic plasticity, learning and memory in vivo.
Additional support for a role of Cdk5 in learning and
memory came from the recently demonstrated impor-
tance of histone acetylation in memory and LTP forma-
tion. Structural remodeling of the chromatin, via acetyla-
tion and deacetylation of histones, has been associated
with activation and silencing of gene expression, respec-
tively. Two recent studies revealed that memory forma-
tion and LTP induction are accompanied by enhanced
histone acetylation, with suppression of histone de-
acetylation markedly enhancing LTP induction and con-
textual fear conditioning in vivo (Alarcon et al., 2004; Lev-
enson et al., 2004). Interestingly, mSds3, an essential
component of the histone deacetylase1 (HDAC1) com-
plex, was recently identified as a Cdk5 substrate.
Cdk5-mediated phosphorylation of mSds3 results in
diminished acetylation of histones, thus elevating
mSds3-mediated transcriptional repression (Li et al.,
2004). This suggests that Cdk5 may also affect memory
formation and LTP induction through regulating histone
deacetylation. Further investigation into this possibility
may shed light on the mechanisms by which Cdk5
affects learning and memory.
Drug Addiction
Drug abuse is associated with modulation of dopamine
signaling in the natural reward pathway. Interestingly,
Cdk5 was recently demonstrated to take part in co-
caine-induced changes in dopamine signaling. Chronic
cocaine exposure leads to prolonged activation of
PKA and accumulation of immediate early gene DFosB.
This results in enhanced expression of Cdk5 and p35,
Neuron
16Figure 2. Signaling Pathways Implicated in
the Regulation of Cdk5 Activity
Signaling pathways affected by Cdk5 in turn
regulates Cdk5 activity. Trophic factors in-
cluding NGF, BDNF, GDNF, and neuregulin
(NRG) have all been observed to increase
Cdk5 activity. In addition to trophic factors,
neurotransmitters such as acetylcholine
(ACh) and glutamate also enhance Cdk5 ac-
tivity. The reported functional importance as-
sociated with the modulation of Cdk5 activity
by the different factors is also indicated.elevating Cdk5 activity. The augmented Cdk5 activity
dampens the effect of chronic cocaine administration
through inhibition of PKA activation (reviewed in Bibb
[2003]). In transgenic mice overexpressing p35, eleva-
tion of Cdk5 activity attenuates cocaine-induced en-
hancement in Thr34 phosphorylated DARPP-32, down-
stream activation of Erk1/2, and the subsequent
activation of transcription factor CREB (Takahashi
et al., 2005). These observations underscore the in vivo
functional significance of Cdk5 induction after chronic
cocaine administration.
On the other hand, elevated Cdk5 activity also con-
tributes to neuroadaptive changes such as regulation
of dendritic spine morphology observed during chronic
cocaine administration (Bibb, 2003; Norrholm et al.,
2003). A recent study revealed that histone acetylation
serves as an essential mechanism by which chronic co-
caine exposure results in neuroadaptive changes (Ku-
mar et al., 2005). Chronic cocaine stimulation leads to
histone acetylation of certain gene promoters including
that of Cdk5, thereby enhancing gene transcription.
Findings from this study not only verify that Cdk5 is in-
duced by chronic cocaine exposure via DFosB in vivo
but also reveal that cocaine-induced transcriptional
and behavioral changes both required histone acetyla-
tion (Kumar et al., 2005). Further delineation on the pre-
cise role of Cdk5 activity in chronic cocaine-induced
neuroadaptive changes is clearly needed. Moreover,
whether Cdk5-mediated regulation of HDAC complex
also contributes to cocaine-induced modification of his-
tones awaits further investigation.
Alzheimer’s Disease
Cdk5 has long been implicated in the pathophysiology
of Alzheimer’s Disease (AD). Deregulation of Cdk5 activ-
ity and calpain-mediated cleavage of p35 into p25 has
been observed in AD brains (reviewed in Cruz and Tsai
[2004]). Indeed, it was recently demonstrated that pro-
longed induction of p25 expression results in impaired
spatial learning, accompanied by brain atrophy and hip-
pocampal neuronal loss (Fischer et al., 2005), thus con-
solidating the potential involvement of Cdk5/p25 in the
pathophysiology of AD. Nonetheless, although most
AD studies have focused on neuronal loss being the ma-
jor cause of dementia, increasing studies suggest that
synapse loss prior to neurodegeneration may providea better correlation with function loss in AD patients. A
recent study revealed that synaptic loss might in part
be accounted for by Ab-induced reduction of NMDA re-
ceptor (Snyder et al., 2005) and surface AMPA receptor
(Roselli et al., 2005). It therefore appears that Ab may di-
rectly affect synaptic transmission through modulation
of glutamatergic synapse composition. Remarkably, re-
duction of surface AMPA receptor is dependent on cal-
cium influx through the NMDA receptor and Cdk5-medi-
ated degradation of PSD-95 (Roselli et al., 2005). The
precise involvement of glutamate signaling and Cdk5
signaling in synaptic functions associated with AD will
undoubtedly remain an important area of research.
Future Perspectives
In this communication, we have reviewed the latest prog-
ress on the role of Cdk5 as a key regulator of synaptic
transmission and synaptic plasticity. Progress from the
past 2 years have not only consolidated the importance
of Cdk5 in the regulation of synaptic transmission
through the identification of novel substrates but have
also provided in vivo evidence for an important role of
Cdk5 in the regulation of learning, memory formation,
and drug addiction. These recent advancements in the
field have highlighted several emerging themes in Cdk5
research deserving our continued effort and attention.
First of all, elucidation of the biological functions of
Cdk5 has relied almost exclusively on the identification
of its substrates. Although this approach has undoubt-
edly led to many interesting and important revelations
on the functional role of Cdk5, our knowledge on the bi-
ological actions of Cdk5 in vivo are lagging behind. Fu-
ture studies directed to elucidating the in vivo actions
of Cdk5 will immensely expand our understanding on
the biological functions of Cdk5. For example, recent
studies with transgenic animals have associated Cdk5
with an increasing number of higher brain functions
and neurodegenerative disease such as drug addiction,
spatial learning, memory formation, and Alzheimer’s
disease. In addition, the exhibition of aberrant excitatory
feedback circuit and spontaneous seizure in p352/2
mice (Patel et al., 2004) reveals that Cdk5 may also con-
tribute to seizure activity. Continued efforts in elucidat-
ing the importance of Cdk5 in these complex functions,
and delineation of the mechanisms implicated, will be
Minireview
17pivotal in providing us with a more complete picture of
Cdk5 action in higher brain functions in vivo.
Cdk5 is potentially involved in several neurological
and psychiatric disorders. Implication of Cdk5 in neuro-
nal death associated with Alzheimer’s and Parkinson’s
disease reveals Cdk5 as a key player in the pathophysi-
ology of these neurodegenerative diseases. With the in-
creasing implication of synaptic dysfunction in the prog-
ress of these neurological disorders, whether Cdk5
affects neurotransmission prior to neuronal death de-
serves further elucidation. Moreover, aberrant synaptic
transmission is also associated with the psychological
disorder schizophrenia. Abnormalities in dopamine, glu-
tamate, acetylcholine, and GABAergic neurotransmis-
sion have all been demonstrated in schizophrenia pa-
tients. Given the regulatory role of Cdk5 in dopamine
and ErbB signaling, it would be of interest to examine
if Cdk5 also modulates the onset and progression of
schizophrenia. The increasing implication of Cdk5 in
a myriad of neurological and psychiatric disorders, and
the observed regulation of dopamine release by Cdk5,
for example, may render Cdk5 a potential target for ther-
apeutic treatment for neurodegenerative diseases such
as Parkinson’s disease. Further investigation on the in-
volvement of Cdk5 in these disorders will not only en-
hance our understanding of this multifaceted kinase
but may also provide novel insights into the treatment
of these disorders.
Finally, although a majority of the studies have fo-
cused on the downstream functions of Cdk5, how
Cdk5 activity is regulated is not well understood. Al-
though several studies have identified pathways that af-
fect Cdk5 activity (Figure 2), the mechanisms implicated
require further exploration. Interestingly, a number of
trophic factors including nerve-growth factor (NGF),
brain-derived neurotrophic factor (BDNF), glial cell-
line-derived neurotrophic factor (GDNF), and NRG
have all been observed to increase Cdk5 activity (Cheng
and Ip, 2003; Dhavan and Tsai, 2001; Ledda et al., 2002).
In addition, recent studies revealed that Cdk5 activity is
also enhanced by neurotransmitters such as ACh and
glutamate (Bibb, 2003; Lin et al., 2005; Wei et al.,
2005). Because receptor tyrosine kinases (RTKs) serve
as cognate receptors for a number of trophic factors
and have also been observed to modulate synaptic
transmission, elucidating the interplay between RTKs
and Cdk5 may shed light on the mechanisms by which
these pathways result in the regulation of Cdk5 activity.
Regardless, given the increasing implication of Cdk5 as
a key regulator of synaptic functions, our understanding
on the biological roles of Cdk5 at synapse will clearly
be far from complete without further characterization
of the pathways involved in the regulation of Cdk5 activ-
ity. More importantly, with the recent association of
Cdk5 with a number of neurodegenerative diseases,
this information will be invaluable in the development
of therapeutic treatment for these neurodegenerative
diseases.
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